Cylexin CY-1503: Phase II trials, expected to start by mid-year.

Cytel Corp. (CYTL), San Diego Product: Cylexin CY-1503, carbohydrate-based, small-molecule blocker of selectin Indication: Reperfusion injury Status: Filed IND for Phase I trials in healthy volunteers...